- Joined
- Mar 17, 2013
- Messages
- 1,337
http://www.gastroendonews.com/ViewA...News&d_id=187&i=May+2014&i_id=1059&a_id=27435
The benefit of keeping patients with Crohn’s disease on an immunomodulator after starting an anti-tumor necrosis factor (TNF) agent appears to differ based on the specific anti-TNF agent used....Outcomes were improved when immunomodulator therapy was continued in patients initiating infliximab but not in those initiating adalimumab or certolizumab.
The benefit of keeping patients with Crohn’s disease on an immunomodulator after starting an anti-tumor necrosis factor (TNF) agent appears to differ based on the specific anti-TNF agent used....Outcomes were improved when immunomodulator therapy was continued in patients initiating infliximab but not in those initiating adalimumab or certolizumab.